Current stock page

Stock Analysis

Celldex Therapeutics, Inc. (CLDX) Stock Analysis

Celldex Therapeutics, Inc. (CLDX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

CLDX Stock Analysis Summary

Celldex Therapeutics, Inc. (CLDX) currently has an AIQ Score of 43/100, indicating a bearish setup. Risk is the strongest factor at 55/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

CLDX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$28.83
AIQ Score43/100
Overall ViewBearish
Technical Analysis ConsensusStrong Sell
Market Cap$2.26B
P/E Ratio (TTM)-6.69
Forward P/E—
EPS (Q3 FY2026)-$0.96
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.22
Volume544.31K
52-week range$22.33-$45.14
RSI 1443.46
50-Day SMA$31.98
200-Day SMA$32.84
Analyst Price Target$69.25
Next EarningsFeb 24, 2027
As of Nov 13, 2026 · Market close

CLDXCelldex Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

BearishEdge 7/10
$28.83+$0.30 (+1.05%)

Latest quote

  • Momentum
    48
  • Value
    —
  • Quality
    30
  • Risk resilience
    55
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

CLDX Stock Analysis Summary

Celldex Therapeutics, Inc. (CLDX) currently has an AIQ Score of 43/100, indicating a bearish setup. Risk resilience is the strongest factor at 55/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, CLDX has AIQ Score of 43/100 with Risk resilience base of 55/100 and fading Quality at 30/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Risk resilience (55/100) leads while Quality (30/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.05% stock move · CLDX classified in Biotechnology.

Current Evidence

BearishCLDX is in a bearish AIQ regime; Risk resilience is the strongest visible factor at 55/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is CLDX Bullish or Bearish Right Now?

CLDX currently has a bearish overall setup. Risk Resilience is the strongest factor at 55/100, while Quality is weakest at 30/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +140.20% upside from the latest quote.
Bear Case
  • - Momentum is weak at 48/100.
  • - Price is -12.21% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (32 vs 7).

Current Consensus

CLDX's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 7 neutral, and 32 sell votes. CLDX's 14-day RSI is 43.46, which places the stock in a weaker momentum range. CLDX's beta is 1.22, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in CLDX?

The largest recent change in CLDX is Momentum moving up by 3.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+3.0
Quality
+1.0
Risk
+0.0

What Would Change the CLDX Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

CLDX Decision Framework

Public evidence layers, setup checks, and risk context for Celldex Therapeutics, Inc..

Celldex Therapeutics, Inc. (CLDX) Stock Analysis

Celldex Therapeutics, Inc. has an AIQ Score of 43/100 in a Bearish regime. Risk is strongest at 55/100. Beta is 1.22, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextCLDX is in a Bearish AIQ regime with score 43/100.
Signal ConflictThe primary conflict is that risk leads at 55/100 while quality lags at 30/100.
Factor EvidenceMomentum 48/100 · Quality 30/100 · Risk 55/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Risk is the strongest factor at 55/100.

TimingFail

Momentum is 48/100 and RSI (14) is 43.5.

Regime fitFail

CLDX is in a Bearish regime at 43/100.

Risk controlWait

Risk factor is 55/100 with beta 1.22 and annual volatility 52.44%.

ConflictWait

Current conflict: risk leads at 55/100 while quality lags at 30/100.

AIQ Score
43/100
Price
$28.83
Beta
1.22
RSI (14)
43.5

CLDX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

CLDX Fundamentals

CLDX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$75.56M
Free cash flow
-$66.7M
View full CLDX fundamental analysis

CLDX Technical Analysis

CLDX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
43.46
Price vs SMA-50
-9.85%
View full CLDX technical analysis

CLDX Stock Catalysts

Track CLDX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 24, 2027
Analyst target
$69.25
News items
5
View CLDX earnings and stock catalysts

CLDX Dividend Analysis

CLDX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View CLDX dividend history and analysis

CLDX Financial Data

CLDX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.96
Periods
8
View CLDX financials

CLDX Risk Analysis

CLDX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.22
Risk score
55/100
1Y volatility
52.44%
View CLDX risk analysis

CLDX Stock News

CLDX stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read CLDX stock news

CLDX vs Biotechnology Peers

Current peer cohort: CLDX · COGT · CYTK · DFTX · DNTH. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
CLDX
Current stock
43/100—48/10055/1000.5552.44%Current
COGT
Cogent Biosciences, Inc.
44/100—45/10051/100-0.2345.96%CLDX vs COGT
CYTK
Cytokinetics, Incorporated
40/10041/10028/10056/100-0.2343.65%CLDX vs CYTK
DFTX
Definium Therapeutics, Inc.
59/100—64/10044/1001.6177.71%CLDX vs DFTX
DNTH
Dianthus Therapeutics, Inc.
56/100—58/10058/1001.8259.79%CLDX vs DNTH
Pairwise Compare links: COGT · CYTK · DFTX · DNTHCLDX vs COGTCLDX vs CYTKCLDX vs DFTXCLDX vs DNTHCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a CLDX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for CLDX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-6.69
As of Nov 13, 2026
Revenue growth
—
Gross margin
-662.50%
Current debt / equity
0.02
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$75.56M
Quarter free cash flow
-$66.7M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
43.46
MACD
-0.57

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
55/100
Beta
1.22
Annual volatility
52.44%
Max drawdown
-38.65%

CLDX Stock FAQ

What is CLDX stock price today?

Celldex Therapeutics, Inc.'s current stock price is $28.83. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is CLDX bullish or bearish right now?

CLDX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is CLDX's market cap?

CLDX's market cap is $2.26B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is CLDX's current P/E ratio?

CLDX's current P/E ratio is -6.69 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is CLDX's RSI?

CLDX's 14-day RSI is 43.46 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is CLDX above its 50-day and 200-day moving averages?

CLDX is -9.85% from its 50-day SMA and -12.21% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is CLDX's next earnings date?

CLDX's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does CLDX pay a dividend?

CLDX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.